ELRIG are delighted to announce that the keynote presentation at Research and Innovation 2016, “Overcoming Commercialisation Challenges for Cell and Gene Therapy,” will be given by Stephen Ward, Chief Operating Officer of Cell Therapy Catapult.
Stephen was appointed as COO of the Cell Therapy Catapult In January 2013, bringing over 17 years of biological medicine research, development, and manufacturing experience to the organisation. Converting early research ideas into regulatory compliant products for patients, Stephen has also developed and validated scalable, commercial manufacturing processes for cell based medicinal products, vaccines, and recombinant biologicals using Quality by Design principles.
We also look forward to hearing presentations from a number of organisations including GlaxoSmithKline, Cancer Research UK, Imperial College London, AstraZeneca, Kings College London, University of Sheffield, as well as many more.
The focus of Research & Innovation 2016 is Cell Biology and Biologics and how new innovations in these fields can be applied to improve the success of drug discovery. There will be presentations from world class speakers and leading industry experts about the challenges and opportunities in developing and applying new thinking across biology to improve the success of drug discovery as well as a vendor exhibition and poster presentations.
The Research & Innovation 2016 tracks are:
- Biopharmaceutical Agents: Innovations from Target to Product
- Stem Cell Biology: A Roadmap for a Moving Landscape
- Synthetic Biology: Engineering complex biological systems
There is also a new technology symposium track:
- Mass Spectrometry: Cornerstone technology for the ‘omics’ revolution.
Deadlines for poster submission are:
12th February 2016 for Poster Taster Sessions
18th March 2016 for general poster submissions
To register free, click here